CS
ACRS icon

Credit Suisse’s Aclaris Therapeutics ACRS Stock Holding History

Credit Suisse’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-135,629
Closed -$142K – 2951
2023
Q4 		$142K Buy
135,629
+36,522
+37% +$111K ﹤0.01% 3010
2023
Q3 		$679K Buy
99,107
+4,463
+5% +$38.1K ﹤0.01% 2517
2023
Q2 		$981K Buy
94,644
+28,352
+43% +$257K ﹤0.01% 2391
2023
Q1 		$536K Buy
66,292
+1,320
+2% +$16.8K ﹤0.01% 2708
2022
Q4 		$1.02M Buy
64,972
+23,580
+57% +$379K ﹤0.01% 2333
2022
Q3 		$652K Buy
41,392
+4,450
+12% +$70.1K ﹤0.01% 2629
2022
Q2 		$515K Buy
36,942
+4,990
+16% +$69.9K ﹤0.01% 2819
2022
Q1 		$550K Buy
31,952
+3,222
+11% +$44K ﹤0.01% 2913
2021
Q4 		$418K Buy
28,730
+1,038
+4% +$15.7K ﹤0.01% 3946
2021
Q3 		$499K Buy
27,692
+1,725
+7% +$27.7K ﹤0.01% 3795
2021
Q2 		$456K Buy
+25,967
New +$590K ﹤0.01% 3899
2019
Q3 		– Sell
-51,593
Closed -$113K – 4099
2019
Q2 		$113K Buy
51,593
+18,153
+54% +$98.9K ﹤0.01% 3939
2019
Q1 		$200K Buy
33,440
+134
+0.4% +$888 ﹤0.01% 3763
2018
Q4 		$245K Buy
33,306
+9,849
+42% +$102K ﹤0.01% 3594
2018
Q3 		$340K Sell
23,457
-16,725
-42% -$287K ﹤0.01% 3470
2018
Q2 		$802K Buy
40,182
+7,563
+23% +$140K ﹤0.01% 3171
2018
Q1 		$571K Buy
32,619
+1,859
+6% +$39.4K ﹤0.01% 3299
2017
Q4 		$759K Buy
30,760
+6,086
+25% +$148K ﹤0.01% 3189
2017
Q3 		$637K Buy
24,674
+14,477
+142% +$388K ﹤0.01% 3403
2017
Q2 		$276K Buy
10,197
+637
+7% +$17.3K ﹤0.01% 3502
2017
Q1 		$286K Sell
9,560
-9,691
-50% -$279K ﹤0.01% 3527
2016
Q4 		$524K Buy
+19,251
New +$491K ﹤0.01% 3416

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's ACRS Position: Q1 2024 in Review

Credit Suisse sold out of Aclaris Therapeutics (ACRS) in Q1 2024, closing a stake of 135,629 shares — an estimated $142K sold.

Credit Suisse first reported a position in ACRS in Q4 2016 and held it in 22 quarters. The position peaked at $1.02M in Q4 2022. 98 funds tracked by Wall St. Rank hold ACRS as of Q1 2024.

  • Credit Suisse reported no remaining Aclaris Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Credit Suisse sold 135,629 Aclaris Therapeutics shares in Q1 2024, an estimated $142K.
  • Credit Suisse first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 22 quarters.
  • Credit Suisse's Aclaris Therapeutics position peaked at $1.02M in Q4 2022.
  • 98 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.